Compare SRRK & BXSL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SRRK | BXSL |
|---|---|---|
| Founded | 2012 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.8B | 5.5B |
| IPO Year | 2018 | 2018 |
| Metric | SRRK | BXSL |
|---|---|---|
| Price | $47.49 | $23.17 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 13 | 10 |
| Target Price | ★ $56.17 | $27.18 |
| AVG Volume (30 Days) | 1.0M | ★ 1.6M |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 12.87% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 0.11 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $534.24 | N/A |
| P/E Ratio | ★ N/A | $210.00 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $27.07 | $22.47 |
| 52 Week High | $58.49 | $31.24 |
| Indicator | SRRK | BXSL |
|---|---|---|
| Relative Strength Index (RSI) | 39.11 | 44.60 |
| Support Level | $45.83 | $22.47 |
| Resistance Level | $48.23 | $24.84 |
| Average True Range (ATR) | 2.20 | 0.42 |
| MACD | -0.65 | -0.03 |
| Stochastic Oscillator | 5.15 | 23.94 |
Scholar Rock Holding Corp is a biopharmaceutical company focused on improving the lives of children and adults with Spinal Muscular Atrophy and other rare, severe, and debilitating neuromuscular diseases. Its pipeline candidates include apitegromab and a subcutaneous formulation of apitegromab. The clinical-stage pipeline also includes SRK-439, an investigational subcutaneously administered fully human anti-pro/latent myostatin antibody with high inhibitory potency and selectivity toward myostatin, being developed for the treatment of rare neuromuscular diseases. The company also maintains early-stage programs focused on therapies for rare, severe, and debilitating neuromuscular diseases.
Blackstone Secured Lending Fund is a non-diversified, closed-end management investment company. The investment objectives of the company are to generate current income and, to a lesser extent, long-term capital appreciation. The company seeks to achieve its investment objectives by investing in originated loans and other securities, including syndicated loans of private U.S. companies, typically in the form of first lien senior secured and unitranche loans, unsecured and subordinated loans, and other securities. The company operates as a single reportable segment and derives revenues from investing in originated loans and other securities, including broadly syndicated loans, of U.S. private companies.